Regencell Bioscience Holdings (Regencell Bioscience Holdings) Scaled Net Operating Assets

: 0.06 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regencell Bioscience Holdings's operating assets for the quarter that ended in Jun. 2023 was $1.06 Mil. Regencell Bioscience Holdings's operating liabilities for the quarter that ended in Jun. 2023 was $0.17 Mil. Regencell Bioscience Holdings's Total Assets for the quarter that ended in Dec. 2022 was $15.55 Mil. Therefore, Regencell Bioscience Holdings's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was 0.06.

Regencell Bioscience Holdings Scaled Net Operating Assets Historical Data

The historical data trend for Regencell Bioscience Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Scaled Net Operating Assets

0.13

-0.73

4.22

0.05

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Scaled Net Operating Assets					-0.63	57.94	0.07	0.81	0.06

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Scaled Net Operating Assets Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Scaled Net Operating Assets falls into.

Regencell Bioscience Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regencell Bioscience Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(1.057	-	0.169)	/	18.019
=	0.05

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	12.622	-	11.565
=	1.057

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.632	-	0.025	-	0.438
=	0.169

Regencell Bioscience Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2023 )
=	(Operating Assets (Q: Jun. 2023 )	-	Operating Liabilities (Q: Jun. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(1.057	-	0.169)	/	15.548
=	0.06

where

	Operating Assets		(Q: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	12.622	-	11.565
=	1.057

	Operating Liabilities		(Q: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.632	-	0.025	-	0.438
=	0.169

Regencell Bioscience Holdings Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.